Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD
Oliver Sartor MD Advisory Board
David Henry MD
David Henry MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · October 12, 2017

Nivolumab in Advanced Gastric or Gastroesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens

The Lancet

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

The Lancet
Nivolumab in Patients With Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet 2017 Oct 05;[EPub Ahead of Print], YK Kang, N Boku, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung, JS Chen, K Muro, WK Kang, KH Yeh, T Yoshikawa, SC Oh, LY Bai, T Tamura, KW Lee, Y Hamamoto, JG Kim, K Chin, DY Oh, K Minashi, JY Cho, M Tsuda, LT Chen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated